Propanc Biopharma Secures $100M for Crypto Treasury, Eyes Cancer Therapy Trials

Key Takeaways:

• Propanc Biopharma secures $100 million from Hexstone Capital to launch a crypto treasury.
• Funds will accelerate the development of their lead cancer therapy, PRP.
• Investor sentiment is mixed, with a dip in PPCB share value.
• The move reflects a broader trend of biotech firms exploring crypto strategies.

Propanc Biopharma, an Australia-based biotech company, has announced a $100 million investment from a crypto-focused family office. This capital injection aims to establish a crypto treasury, a move described by the CEO as pivotal for advancing their cancer therapy product into human trials next year.

The private placement, structured via convertible preferred stock, grants Propanc an initial $1 million investment, with the potential for up to $99 million in subsequent funding over the next year from Hexstone Capital, a family office actively investing in crypto treasury ventures.

The company intends to allocate these resources to build a robust digital asset treasury and expedite the development of PRP, their primary cancer therapy. The goal is to commence first-in-human trials in the latter half of 2026.

According to Propanc CEO James Nathanielsz, the crypto treasury marks a "transformative phase" for the company, bolstering its financial stability and facilitating advancements in its proenzyme-based oncology platform. "We aim to target not only metastatic cancer patients with solid tumors but also various chronic diseases, leveraging the mechanism of action inherent in proenzyme therapy."

While the specific digital assets intended for the treasury remain undisclosed, Hexstone's clientele has diversified holdings in cryptocurrencies ranging from Bitcoin (BTC), Ether (ETH), Solana (SOL), and Injective (INJ), to lesser-known altcoins.

Biotech Companies Embracing Crypto Strategies

Propanc is the latest biotech company to venture into the crypto space, joining the ranks of Sonnet BioTherapeutics, Sharps Technology, and others who see digital assets as a means to revitalize investor interest.

However, the market's initial response to Propanc's strategy has been cautious, with PPCB shares experiencing a 10.5% decline on the Nasdaq on Monday, based on data from Yahoo Finance.

Recent Performance of Crypto Treasury Strategies

The allure of Bitcoin treasury holding companies has diminished somewhat in recent months as competition increases.

Even Strategy, the largest corporate Bitcoin holder, has witnessed a significant market cap reduction, falling over 43% from $122.1 billion in July to $69.1 billion currently.

Metaplanet, previously a top-performing stock on the Tokyo Stock Exchange, has suffered a steeper decline, plummeting approximately 55% since late June. Some Bitcoin treasury companies have even been compelled to liquidate portions of their BTC holdings to meet outstanding debt obligations.